Abstract: Described herein are novel LIF/LIFR inhibitors that exhibit improved cytotoxicity and bioavailability. These LIF/LIFR inhibitors are particularly useful for the treatment of tumors associated with overexpression of LIF.

Abstract: An article dispensing system and method that has a first and a second vibratory feeder; a rotary trough dispenser having one or more receiving troughs in which counted or weighed articles are dispensed for packaging; while the next trough within the rotary trough dispenser is indexed in a rotational step-wise fashion.

Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.

Abstract: Described herein are methods of using compounds that inhibit leukemia inhibitory factor (LIF) and/or block of the leukemia inhibitory factor receptor for treatment of liver fibrosis, proliferation of spinal tumors, and in combination therapy with an immunotherapeutic agent.

Abstract: The present disclosure, in various embodiments, describes technologies and techniques for use by a data storage controller for decoding codewords during an error correction read recovery process. In illustrative examples, an iterative procedure exploits artificial codewords generated using information obtained from a NAND or other non-volatile memory (NVM) in a previous sense operation. That is, procedures are described that use information obtained in one stage of read recovery to facilitate a subsequent stage to reduce the need to perform additional NAND senses. In one example, information obtained from a sense operation performed for an initial hard bit decode is used in subsequent soft bit decodes. Moreover, iterative decoding procedures are provided that progressively increase correction strength. The procedures may alternate between hard and soft reads while using syndrome weight to determine a failed bit code gradient for identifying the sensing voltage for a next hard sense.

Abstract: The present disclosure, in various embodiments, describes technologies and techniques for use by a data storage controller for decoding codewords during an error correction read recovery process. In illustrative examples, an iterative procedure exploits artificial codewords generated using information obtained from a NAND or other non-volatile memory (NVM) in a previous sense operation. That is, procedures are described that use information obtained in one stage of read recovery to facilitate a subsequent stage to reduce the need to perform addition NAND senses. In one example, information obtained from a sense operation performed for an initial hard bit decode is used in subsequent soft bit decodes. Moreover, iterative decoding procedures are provided that progressively increase correction strength. The procedures may alternate between hard and soft reads while using syndrome weight to determine a failed bit code gradient for identifying the sensing voltage for a next hard sense.

Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Abstract: Described herein are progestin compounds that have extended release rates and that can be used without an estrogen to produce a contraceptive state.

Abstract: A product speed checking apparatus for attaching to a vibratory conveying system and a method thereof for dispensing product, including a sample pan mounted to capture flow of product between two vibratory conveyors; a first sensor and a second sensor, each placed separately at a predetermined distance from one another and each capable of independently reading product handled by the sample pan; and, a programmable logic controller operatively arranged to calculate an approximate time between the reading of product by the first sensor and the reading of product by the second sensor and computing product speed by dividing distance between two sensors with the travel time between the two sensors.

Abstract: A product speed checking apparatus for attaching to a vibratory conveying system and a method thereof for dispensing product, including a sample pan mounted to capture flow of product between two vibratory conveyors; a first sensor and a second sensor, each placed separately at a predetermined distance from one another and each capable of independently reading product handled by the sample pan; and, a programmable logic controller operatively arranged to calculate an approximate time between the reading of product by the first sensor and the reading of product by the second sensor and computing product speed by dividing distance between two sensors with the travel time between the two sensors.

Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Abstract: The various implementations described herein include systems, methods and/or devices used to enable adaptive verify voltage adjustment in memory devices. The method includes: (1) in conjunction with decoding data read from non-volatile memory in the non-volatile memory system, determining a plurality of error parameters, (2) determining, in accordance with the plurality of error parameters, a verify adjustment signal, (3) determining whether a verify trigger event has occurred, (4) in accordance with a determination that a verify trigger event has occurred, adjusting a verify voltage in accordance with the verify adjustment signal, and (5) performing data write operations to write data to non-volatile memory in the non-volatile memory system using the adjusted verify voltage to verify the data written using the data write operations.

Abstract: Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Abstract: A method and apparatus for checking the weighing one or more objects in a vibratory apparatus comprising the steps of accepting product into an in-line feeder to a discharge feeder without being weighed, determining an angle of decline of a fixed chute and a rotating chute based upon the flowing characteristics of the free flowing material being transferred, generating a sampling signal by a control system, the sampling signal causing the air cylinder to rotate the rotating chute in the position to capture the free flowing material and weighing the in-line sample for comparison purposes with the calculated weight.

Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: Compounds of the formula are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.